MedPal AI raises £5m as MPAL buys eMAR software and backs oral Wegovy launch

MedPal AI plc (AIM: MPAL) has conditionally raised £5 million to acquire electronic medicines administration software provider Solid State Technologies Ltd and finance its expansion into the United Kingdom’s newly approved oral GLP-1 weight-loss market. The company plans to allocate approximately £500,000 to the acquisition and integration of Solid State Technologies, up to £3 million to medicine inventory and patient acquisition for oral Wegovy, and the remaining proceeds to pharmacy growth and working capital. MedPal AI will issue approximately 153.8 million fundraising and settlement shares, increasing its issued share capital by close to 25% and reducing the collective ownership of existing shareholders who do not participate. MPAL shares closed 8.75% lower at 3.65 pence on July 3 as investors weighed the potentially attractive acquisition economics against dilution, marketing risk and the company’s continuing dependence on equity capital.

Why is MedPal AI raising £5 million only months after its previous equity financing?

MedPal AI has moved rapidly from being a pre-revenue digital wellness application into a vertically integrated healthcare, pharmacy and medication-management company. That transformation has required acquisitions, dispensing infrastructure, clinical personnel, marketing expenditure, medicine inventory and technology development before the enlarged platform has generated enough cash to fund itself.

The company raised approximately £2 million when it joined AIM in August 2025 and subsequently raised close to another £2 million through an at-the-market equity facility. It then secured £3 million through a placing in April 2026, together with other smaller capital raises, before announcing the latest £5 million financing.

The latest placing is therefore part of a broader pattern rather than a one-off funding event. MedPal AI is attempting to compress several years of healthcare platform development into a much shorter period, using public equity to acquire regulated infrastructure and capture market opportunities as they emerge.

Management’s argument is that the latest capital is being raised for growth rather than corporate survival. The proceeds have clearly defined uses, including a profitable software acquisition, oral GLP-1 stock, customer acquisition and working capital for rising prescription volumes.

However, the distinction between growth capital and survival capital can become blurred when a company remains loss-making. MedPal AI reported a £3.27 million loss for the six months ended February 2026 against revenue of £1.60 million. Until operating cash flow turns positive, at least part of every financing provides the liquidity required to sustain the wider organisation while management pursues expansion.

The strategic opportunity may justify accelerated investment, but the funding sequence increases the burden on management. Each placing must create enough additional enterprise value to offset the cumulative ownership reduction experienced by existing shareholders.

How much dilution will the MedPal AI fundraising create for existing MPAL investors?

MedPal AI is issuing approximately 142.86 million shares through the placing at 3.5 pence each. The company will also issue approximately 10.94 million shares to settle contractual obligations with consultants and service providers.

The combined issuance of 153.8 million shares compares with approximately 616.04 million shares currently outstanding. Following admission, the total share count will rise to approximately 769.84 million.

This represents an increase of almost 25% in the issued share capital. Existing shareholders who do not acquire additional shares will collectively own approximately 80% of the enlarged company, equivalent to ownership dilution of about 20%.

OAK Securities has also been granted warrants over approximately 8.57 million shares at the 3.5 pence placing price. Full exercise would produce additional cash for MedPal AI, but it would create another layer of dilution.

The 3.5 pence placing price represented a 12.5% discount to the previous closing mid-market price of 4 pence. The price was nevertheless 40% above the 2.5 pence level used during MedPal AI’s April financing.

This comparison supports management’s claim that the company has made operational progress since April. Raising money at a higher price reduces the number of shares required for each pound of capital. However, a higher placing price does not eliminate dilution when the financing remains large relative to the company’s market value.

At the July 3 closing price, MedPal AI’s pre-admission equity value was approximately £22.5 million. Applying the same share price to the enlarged share count would produce a theoretical post-admission market capitalisation of about £28.1 million.

The investment case therefore requires Solid State Technologies, the oral Wegovy launch and pharmacy growth to create several million pounds of sustainable value. Without that growth, the larger market capitalisation would simply reflect the additional cash and shares rather than a stronger underlying business.

Why could Solid State Technologies be the most attractive part of the £5 million financing?

Solid State Technologies provides electronic medicines administration record software used at the point where care-home staff give medicines to residents. Its system is intended to document administration, flag missed doses, maintain audit records and connect medication activity with prescribing and pharmacy workflows.

MedPal AI already supplies medicines to care homes through its pharmacy operations. Adding the electronic administration layer could allow the company to connect prescribing, dispensing, delivery, administration and reconciliation within one platform.

This could create a stronger customer relationship than a conventional pharmacy supply contract. Changing pharmacy supplier may be relatively straightforward when the service is limited to dispensing and delivery. Switching becomes more disruptive when the supplier also provides the care home’s medication records, staff workflows, alerts and audit trails.

Solid State Technologies recorded annualised management-account revenue of approximately £843,000 and annualised profit of around £307,000 to May 31, 2026. MedPal AI has agreed to pay no more than £500,000 for the business.

On those figures, the proposed consideration represents approximately 0.6 times annualised revenue and 1.6 times annualised profit. Those multiples appear unusually low for profitable recurring healthcare software.

The pricing could make the deal highly accretive if the earnings are sustainable. Annualised profit of £307,000 would theoretically recover a £500,000 purchase price in less than two years before integration costs, tax, working-capital requirements and any changes in customer retention.

Investors should not assume that the headline multiple tells the entire story. The financial figures come from recent management accounts rather than a long audited history, and MedPal AI has not disclosed customer concentration, contract durations, cash conversion, software-development costs or potential liabilities.

The acquisition also remains subject to formal completion. MedPal AI must demonstrate that the customer base, intellectual property and financial performance survive the ownership change.

Even with those reservations, Solid State Technologies may offer more predictable economics than the company’s consumer weight-loss expansion. It brings existing revenue, reported profitability and direct integration with care-home customers MedPal AI already serves.

Can MedPal AI create a defensible closed-loop medication platform for care homes?

Care-home medication management involves several separate activities that are often handled through different systems and organisations. Prescriptions must be generated and reviewed, medicines must be dispensed and delivered, care-home workers must record each administration, and discrepancies must be reconciled.

Fragmentation can create administrative work, delayed information and opportunities for error. A connected platform can provide a clearer record of what was prescribed, what was supplied and whether each medicine was administered.

MedPal AI’s two automated dispensing hubs give it physical pharmacy infrastructure. The acquisition of Solid State Technologies would add software operating within care homes, while the wider MedPal platform provides digital engagement and clinical services.

This could produce valuable operating data. MedPal AI may be able to forecast repeat prescriptions, identify missed administrations, improve stock planning and reduce unnecessary emergency deliveries. Better information could also strengthen relationships with care-home operators and National Health Service commissioners.

The strategic advantage depends on interoperability. Care homes, general practitioners, pharmacies and clinical systems may use different software, data formats and security requirements. MedPal AI must ensure that its platform can exchange information reliably while maintaining patient confidentiality and regulatory compliance.

The company must also avoid making customers feel trapped. Healthcare buyers may resist a closed platform if data portability is weak or if one supplier controls too many essential processes.

A successful model would create convenience and lower operating costs without limiting customer choice. A poorly executed model could become an expensive combination of pharmacy infrastructure and software systems that require constant custom integration.

The acquisition gives MedPal AI a credible route to recurring business-to-business software revenue. It must now show that the combined offering can increase customer retention, improve margins and generate cross-selling rather than simply adding another operating unit.

Why is MedPal AI committing up to £3 million to the oral Wegovy opportunity?

The United Kingdom approved the first GLP-1 tablet for weight loss and weight management on June 11, 2026. The oral formulation could expand the market by attracting eligible patients who are reluctant to use weekly injections.

MedPal AI intends to sell the treatment through New Health, its dedicated private weight-management platform. The service combines digital patient acquisition, clinician-led assessment, prescribing where appropriate, medicine dispensing and ongoing monitoring.

The company expects each active private patient to generate approximately £2,400 of recurring annual revenue. On that basis, 1,000 active patients would represent roughly £2.4 million of annualised revenue, while 5,000 patients would represent approximately £12 million.

Those numbers explain why management is willing to deploy substantial capital quickly. A successful launch cohort could transform MedPal AI’s revenue base and increase utilisation across its clinical and pharmacy infrastructure.

However, revenue per patient is not the same as profit per patient. MedPal AI must pay for medicine inventory, clinical assessments, delivery, customer service, payment processing, technology, marketing and regulatory compliance.

The proposed £3 million allocation combines inventory with patient-acquisition expenditure, making it difficult to determine the implied marketing budget or expected customer-acquisition cost. At £2,400 of annual revenue per patient, £3 million is equivalent to the gross annual revenue from approximately 1,250 active patients.

MedPal AI will need substantially more than 1,250 patient-years to recover the investment profitably because medicine and service costs consume part of the revenue. Retention will be equally important, since patients who discontinue treatment quickly may not generate enough contribution to repay acquisition spending.

How intense will competition become in the United Kingdom private GLP-1 market?

The private weight-management market has attracted online pharmacies, digital-health companies, established pharmacy chains and specialist subscription providers. MedPal AI has identified MedExpress, Voy, Juniper and Hims as direct competitors.

These businesses compete through pricing, brand recognition, clinical support, convenience and access to medicine supply. Customer-acquisition costs can rise rapidly when several providers bid for the same search terms, social-media audiences and affiliate channels.

MedPal AI’s main proposed advantage is vertical integration. The company owns dispensing infrastructure and operates clinical and consumer-facing platforms, potentially allowing it to control more of the patient journey than providers relying heavily on third-party pharmacies.

Owned infrastructure can improve service speed and retain more gross margin. It can also become a fixed-cost burden if patient volumes fail to reach expectations.

Supply relationships with Novo Nordisk A/S and Eli Lilly and Company may help MedPal AI secure medicines, but major competitors will also seek reliable supply arrangements. Access to stock is an advantage only if competing providers face shortages or allocation constraints.

The oral formulation could expand the total market, but it may also lower barriers for traditional pharmacies and other telehealth businesses. A tablet is easier to store, distribute and explain than an injectable treatment, potentially increasing the number of providers.

MedPal AI must therefore compete through more than early inventory. Sustainable differentiation will require efficient fulfilment, trusted clinical governance, effective retention and lower customer-acquisition costs.

Does MedPal AI’s pharmacy growth support the claim that its infrastructure can scale?

MedPal AI generated revenue of £1.60 million and gross profit of approximately £368,550 during the six months ended February 2026. By March, its pharmacy operation had reached an annualised revenue run rate above £5 million.

The company dispensed more than 42,250 prescription items during May, its strongest month since operations began. Cumulative dispensing had exceeded 250,000 items, while pharmacy gross margins had reportedly moved above 34%.

These figures indicate genuine commercial activity rather than a purely conceptual healthcare platform. Rising prescription volumes also provide operational experience that may be useful when adding care-home customers and private weight-management patients.

However, the group-level loss of £3.27 million demonstrates that pharmacy gross profit has not yet covered technology development, clinical staffing, marketing and corporate expenditure.

Gross margin improvement is encouraging, but investors need operating cash-flow evidence. A pharmacy can report attractive gross margins while consuming cash through stock purchases, receivables, delivery costs and customer acquisition.

The acquisition of the Runcorn pharmacy assets adds capacity and historical care-home relationships, but MedPal AI must reactivate patients and rebuild volumes rather than assume that all former business will return automatically.

The next financial results should provide dispensing revenue, private-clinic revenue, software revenue, gross margin and cash expenditure separately. Without segment clarity, investors may struggle to determine which growth engine is creating value and which is consuming capital.

Why did MPAL shares fall despite the acquisition and oral Wegovy growth opportunity?

MPAL closed at 3.65 pence on July 3, down 8.75% from the previous 4 pence close. More than 50 million shares changed hands, indicating a meaningful reassessment rather than an illiquid price movement.

The placing price of 3.5 pence created an immediate valuation reference only slightly below the market close. Investors buying in the market had little reason to pay a substantial premium while 142.86 million new shares were due to be admitted at the lower price.

MPAL had also risen strongly before the financing. The shares were approximately 35% above their June 3 level, supported by oral Wegovy approval, record prescription volumes and enthusiasm around the New Health strategy.

Across the five sessions ending July 3, however, the stock fell by roughly 21%. The decline suggests that investors are distinguishing between the size of the market opportunity and the capital required to pursue it.

Available market data placed MPAL’s 52-week range between approximately 2.15 pence and 12.25 pence. The stock therefore remains well above its annual low but around 70% below its peak.

Investor sentiment appears speculative rather than settled. The market recognises rapid revenue growth and a potentially cheap software acquisition, but it also sees repeated equity issuance, significant losses and an ambitious plan spanning artificial intelligence, National Health Service pharmacy services, care homes and consumer weight management.

The shares are likely to remain highly sensitive to dispensing updates, New Health patient numbers and any indication of further fundraising.

What must MedPal AI prove before the £5 million placing can create lasting value?

The first requirement is completion of the Solid State Technologies acquisition on the stated terms. MedPal AI should provide audited or independently verified financial information, customer-retention data and integration milestones.

The second requirement is evidence that care-home customers adopt the combined software and pharmacy platform. Investors need to see contract wins, recurring software revenue and improved retention rather than only a description of the closed-loop model.

The third requirement is transparent oral Wegovy economics. MedPal AI should disclose active patient numbers, customer-acquisition costs, average revenue, treatment retention and contribution margin without compromising patient confidentiality.

The fourth requirement is sustained pharmacy growth. Dispensing volumes should increase while gross margins remain stable and working-capital requirements stay controlled.

The fifth requirement is a credible route to cash-flow breakeven. The company has accumulated several revenue opportunities, but equity investors cannot finance every stage indefinitely.

MedPal AI may have assembled the components of a differentiated healthcare platform at considerable speed. The next phase is less glamorous but more important. Management must prove that the components generate cash more effectively together than they would as separate businesses.

Key takeaways on what MedPal AI’s £5 million placing means for MPAL investors

• MedPal AI has raised £5 million at 3.5 pence per share, a 12.5% discount to the previous closing price.
• Fundraising and settlement shares will increase the issued share count by almost 25%.
• Existing shareholders who do not participate will experience ownership dilution of approximately 20%.
• Solid State Technologies brings reported annualised revenue of £843,000 and annualised profit of £307,000.
• The maximum £500,000 acquisition price appears low, but the figures are based on management accounts and require further verification.
• Up to £3 million will support oral Wegovy inventory and customer acquisition through the New Health platform.
• MedPal AI’s forecast £2,400 of annual revenue per active patient should not be confused with profit or cash contribution.
• Pharmacy dispensing volumes are growing, but the group reported a £3.27 million interim loss.
• MPAL fell 8.75% after the placing and was approximately 21% lower over five trading sessions.
• Sustainable value creation now depends on software integration, patient retention, pharmacy margins and a clear path to cash-flow breakeven.